Ness Ziona, Israel – May 14, 2020BiomX Inc. (the “Company”) (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Thursday, May 14, 2020, at 8:00 a.m. ET to report first quarter 2020 financial results and provide a corporate update.

To participate in the conference call, please register at http://dpregister.com/10144165 ahead of the call to receive the dial-in information. A live webcast of the call will be available on the Investors section of the BiomX website and a replay will be available after its completion.

About BiomX
BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

www.biomx.com

Company Contact
BiomX
Noel Kurdi
VP, Investor Relations and Strategy
(646) 241-4400
noelk@biomx.com